{
 "query": "amphetamine / dextroamphetamine",
 "ingredient": "amphetamine / dextroamphetamine",
 "slug": "amphetamine-dextroamphetamine",
 "rxcui": "253146",
 "brands": [
  "Adderall",
  "Mydayis"
 ],
 "names": [
  "amphetamine / dextroamphetamine"
 ],
 "components": [
  {
   "ingredient": "amphetamine",
   "slug": "amphetamine",
   "grade": "C",
   "total": 74,
   "scores": {
    "safety": "F",
    "evidence": "B",
    "regulatory": "B",
    "conflict": "A",
    "options": "A"
   },
   "boxed": true,
   "controlled": true,
   "first_approval_fmt": "02/26/1976",
   "first_approval": "19760226"
  },
  {
   "ingredient": "dextroamphetamine",
   "slug": "dextroamphetamine",
   "grade": "D",
   "total": 60,
   "scores": {
    "safety": "D",
    "evidence": "F",
    "regulatory": "C",
    "conflict": "B",
    "options": "A"
   },
   "boxed": true,
   "controlled": true,
   "first_approval_fmt": "05/29/1975",
   "first_approval": "19750529"
  }
 ],
 "classes": [],
 "alternatives": [],
 "label": {},
 "faers": null,
 "faers_base": {
  "total": 20692304,
  "serious_share": 0.5742697381596559,
  "death_share": 0.09102355155810585
 },
 "recalls": [],
 "recall_total": 0,
 "drugsfda": {
  "first_approval": "19750529",
  "first_approval_fmt": "",
  "anda": 19,
  "nda": 0,
  "rems": false,
  "labeling_recent": 0
 },
 "trials": null,
 "pubmed": null,
 "payments": {
  "year": "2024",
  "usd": 0.0,
  "records": 0,
  "by_name": [],
  "names_checked": [
   "amphetamine / dextroamphetamine",
   "Adderall",
   "Mydayis"
  ],
  "source": "bulk-index"
 },
 "partd": {
  "year": "2024",
  "claims": 2508114,
  "beneficiaries": 369620,
  "spend": 111966169.32000001,
  "by_brand": [
   {
    "brand": "Dextroamphetamine-Amphetamine",
    "claims": 1740464,
    "per_claim": 29.427503212,
    "is_generic": false
   },
   {
    "brand": "Dextroamphetamine-Amphet ER",
    "claims": 710833,
    "per_claim": 53.765538896,
    "is_generic": false
   },
   {
    "brand": "Adderall XR",
    "claims": 39181,
    "per_claim": 308.84240499,
    "is_generic": false
   },
   {
    "brand": "Adderall",
    "claims": 13734,
    "per_claim": 662.94240789,
    "is_generic": false
   },
   {
    "brand": "Mydayis",
    "claims": 3902,
    "per_claim": 339.50147617,
    "is_generic": false
   }
  ],
  "per_claim": 44.6415790191355
 },
 "mdl": [],
 "dsc": [],
 "settlements": [],
 "prescrire": null,
 "eml": null,
 "exposure": null,
 "scores": {
  "safety": {
   "score": 48,
   "letter": "F",
   "why": [
    "Graded by its riskiest ingredient, amphetamine (48)",
    "Carries an FDA boxed warning, the strongest warning the FDA issues (-30)",
    "Federally controlled substance: dependence and misuse risk (-10)",
    "Death appears in 4.6x the share of reports seen across all of FAERS (-12)"
   ],
   "weight": 0.35
  },
  "evidence": {
   "score": 33,
   "letter": "F",
   "why": [
    "Graded by its riskiest ingredient, dextroamphetamine (33)",
    "66 randomized trials and 0 systematic reviews/meta-analyses indexed in PubMed",
    "No Cochrane review found (-5)",
    "'Drug ineffective' is the single most-reported item about this drug in FAERS (-5)"
   ],
   "weight": 0.25
  },
  "regulatory": {
   "score": 74,
   "letter": "C",
   "why": [
    "Graded by its riskiest ingredient, dextroamphetamine (74)",
    "Recalls since 2016: 1 Class I, 1 Class II, 0 Class III across 30 generic makers (-18)",
    "8 label changes approved since 2021: the safety story is still moving (-8)"
   ],
   "weight": 0.15
  },
  "conflict": {
   "score": 85,
   "letter": "B",
   "why": [
    "Graded by its riskiest ingredient, dextroamphetamine (85)",
    "Pharma paid doctors $507,930 tied to this drug last year (-15)",
    "Not named in any pending federal MDL"
   ],
   "weight": 0.15
  },
  "options": {
   "score": 100,
   "letter": "A",
   "why": [
    "Graded by its riskiest ingredient, amphetamine (100)",
    "Generic versions approved (19 applications)",
    "12 same-class alternatives exist"
   ],
   "weight": 0.1
  }
 },
 "total": 59,
 "grade": "D",
 "questions": [
  "This is a fixed combination of amphetamine and dextroamphetamine. Why both together, instead of only the one I need?",
  "This drug carries a boxed warning. Which specific risk does it cover, and does it apply to me?",
  "This is a controlled substance. What is the plan for how long I take it and how I stop?",
  "The most-reported problems in FDA's adverse event data are toxicity to various agents, drug abuse, completed suicide, overdose. How would we recognize and handle those?",
  "Why this one over armodafinil, atomoxetine, dexmethylphenidate? What would make you pick one of those instead?",
  "What result are we expecting, by when, and what is the plan if it does not happen?",
  "If 100 people like me took this drug, how many would actually get better because of it, and how many would be harmed by it? (Doctors call these the number needed to treat and the number needed to harm.)",
  "The most-reported problems in FDA's adverse event data are fatigue, anxiety, nausea. How would we recognize and handle those?",
  "Why this one over amphetamine, armodafinil, atomoxetine? What would make you pick one of those instead?"
 ]
}